Amgen Invests $200 Million in Monoclonal Antibodies
Amgen Invests $200 Million in Monoclonal Antibodies
Amgen recently announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing approximately $200 million to build an innovative new facility, which will initially focus on expanding Amgen’s manufacturing capability for monoclonal antibodies. The facility will be capable of manufacturing both clinical and commercial products.
“Amgen is pleased to be planning for a new world-class facility in Singapore as part of our global expansion strategy. Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” said Madhu Balachandran, Executive Vice President of Operations at Amgen.
Construction is expected to begin in the next few months, and the site will be staffed with both new recruits and experienced staff. Amgen is currently partnering with local universities to recruit for a number of positions in Manufacturing and Quality.
As one of the industry’s original innovators, Amgen has extensive knowledge and first-hand expertise in clinical and commercial manufacturing of biotechnology-based medicines as well as a track record of safely and reliably delivering medicines to patients who need them. Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. To learn more about its pioneering science and its vital medicines, visit www.amgen.com or follow them on www.twitter.com/amgen.
Total Page Views: 1291
